Skip to main content
Premium Trial:

Request an Annual Quote

Bruker to Pocket at Least $14.7M in Stock Offering

NEW YORK (GenomeWeb News) — Bruker BioSciences today said it expects to pocket at least $14.7 million after issuing a stock offering.
 
The company said proceeds from the sale may be used for general purposes, repaying debts, and potential acquisitions. 
 
The company said it expects to sell 10.4 million shares at $7.10 apiece. Bruker said it expects selling stockholders to earn roughly $54.9 million. 
 
Bruker said 2.2 million shares will be sold through the company and 8.2 million will be offered through four stockholders. 
 
Bruker said it also has offered underwriters an option to buy an additional 330,000 shares, and selling stockholders have offered an option to buy 1.23 million shares.
 
This additional offering should bring in an extra $2.2 million for the company and $8.3 million for the stockholders.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.